Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep 19:16:17588359241272957.
doi: 10.1177/17588359241272957. eCollection 2024.

Efficacy of carboplatin-etoposide rechallenge after first-line chemo-immunotherapy in ES-SCLC: an international multicentric analysis

Igor Gomez-Randulfe  1 , Sofía Silva Díaz  2 , Carles Escriu  3 , Saara Mohammed  4 , Riyaz Shah  4 , Javier David Benitez Fuentes  5 , Samantha Cox  5 , Federico Monaca  6 , Emilio Bria  6 , María Rosario García-Campelo  2 , Benjamin Crook  7 , Toby Talbot  7 , Rita Leporati  8 , Kirsty Balachandran  9 , Tom Newsom-Davis  9 , Sarah Hughes  1 , Laura Cove-Smith  1 , Paul Taylor  1 , Fiona Blackhall  1   10 , Raffaele Califano  11
Affiliations

Efficacy of carboplatin-etoposide rechallenge after first-line chemo-immunotherapy in ES-SCLC: an international multicentric analysis

Igor Gomez-Randulfe et al. Ther Adv Med Oncol. .

Abstract

Background and objectives: Second-line treatment for small-cell lung cancer (SCLC) is primarily guided by the time elapsed since the last platinum dose. Rechallenge with carboplatin and etoposide has demonstrated superior outcomes compared to topotecan if the platinum-free interval (PFI) is longer than 90 days and is considered the standard of care. However, these findings predate the chemo-immunotherapy era. This study investigates the effectiveness of the rechallenge strategy after chemo-immunotherapy in a real-world setting.

Design and methods: We retrospectively reviewed patients with the extensive stage (ES)-SCLC who received rechallenge with carboplatin and etoposide after first-line chemoimmunotherapy between September 2020 and August 2023 in nine European centres. Demographic and clinical data were collected and analysed.

Results: A total of 93 patients were included. Sixty-six (71%) patients had a PFI between 3 and 6 months. Consolidation thoracic radiotherapy and prophylactic cranial irradiation had been administered in 31 (33.3%) patients and 20 (21.5%) patients, respectively. Overall response rate was 59.1%. Median progression-free survival (PFS) was 5 months (95% confidence interval (CI) 4.3-5.7) and median overall survival (OS) was 7 months (95% CI 5.7-8.3). Notably, PFS and OS were not different according to PFI (3-6 m vs > 6 m).

Conclusion: Rechallenge with carboplatin and etoposide is a valid second-line option in patients with ES-SCLC whose disease progresses after first-line chemoimmunotherapy. Our analysis shows similar results to previous studies. Furthermore, outcomes were consistent across patients with different PFIs, confirming its efficacy in patients with a PFI longer than 3 months.

Keywords: carboplatin and etoposide; chemoimmunotherapy; immunotherapy; rechallenge; small-cell lung cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there is no conflict of interest.

Figures

Figure 1.
Figure 1.
Kaplan–Meier curves for progression-free survival in patients with a PFI between 3 and 6 months and >6 months. PFI, platinum-free interval.
Figure 2.
Figure 2.
Kaplan–Meier curves for overall survival in patients with a PFI between 3 and 6 months and >6 months. PFI, platinum-free interval.
See this image and copyright information in PMC

References

    1. Wang Q, Gümüş ZH, Colarossi C, et al.. SCLC: epidemiology, risk factors, genetic susceptibility, molecular pathology, screening, and early detection. J Thorac Oncol 2023; 18(1): 31–46. - PMC - PubMed
    1. Giunta EF, Addeo A, Rizzo A, et al.. First-line treatment for advanced SCLC: what is left behind and beyond chemoimmunotherapy. Front Med (Lausanne) 2022; 9: 924853. - PMC - PubMed
    1. Horn L, Mansfield AS, Szczęsna A, et al.. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med 2018; 379(23): 2220–2229. - PubMed
    1. Goldman JW, Dvorkin M, Chen Y, et al.. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2021; 22(1): 51–65. - PubMed
    1. Rudin CM, Awad MM, Navarro A, et al.. Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: randomized, double-blind, phase III KEYNOTE-604 study. J Clin Oncol 2020; 38(21): 2369–2379. - PMC - PubMed

LinkOut - more resources